2) Now we are covering @ASH_hematology 2022 #ASH22, which just occurred in December! Our expert guides are Joseph Mikhael MD @jmikhaelmd of @cityofhope and #CEO of @IMFmyeloma, and Dr. Beth Faiman @BethFaiman from @ClevelandClinic.
— @onc_ce (@onc_ce) February 1, 2023
3b) This 🆓CE/#CME program from @onc_ce & its companion website https://t.co/InvUb0y4CV are supported by an educational grant from Sanofi. Content is intended for #healthcare providers. Statement of accreditation and faculty disclosures are listed at https://t.co/L3Mqp0MCSE. pic.twitter.com/0o3sBarnLR
— @onc_ce (@onc_ce) February 1, 2023
5) Let's get started! Which of the following is not a current approved strategy for treating patients with #RRMM and 1-3 prior lines of therapy?
— @onc_ce (@onc_ce) February 1, 2023
a. #anti_CD38 + #pom_dex
b. #proteosome_inhibitor + #IMID + dex
c. #selinexor + bortezomib + dex
d. #CART therapy
6b) This underscores a need for newer targets, and better combination therapies #multiplemyeloma #mmsm
— @onc_ce (@onc_ce) February 1, 2023
See 🔓 https://t.co/wzXi25kcwL pic.twitter.com/1jMhG04NTv
8a) In the Phase 3 #ICARIA_MM study, #isatuximab (#Isa), an anti-#CD38 monoclonal antibody, was shown to be #safe and #effective when given in combination with #pomalidomide and dexamethasone (Pd).
— @onc_ce (@onc_ce) February 1, 2023
See https://t.co/wPHHJo1Kcp pic.twitter.com/dfdMlG0XN7
9) In #ICARIA_MM, patients were randomized 1:1 to Isa-Pd (n=154) or Pd (n=153) w/ stratification by age (<75 vs ≥75) and number of prior LOT (2–3 vs >3), with treatment until #PD, unacceptable toxicities, or patient desire to withdraw from study. Next….. pic.twitter.com/RehntfRPck
— @onc_ce (@onc_ce) February 1, 2023
10b) (cont)
— @onc_ce (@onc_ce) February 1, 2023
(median: 24.6 vs 17.7 months; hazard ratio 0.776 [95% CI: 0.594–1.1015]; one-sided P=0.0319; significance level: P=0.02).
See (nonaccredited) video here: 🔗https://t.co/FNehiIlfsc
11b) Not surprisingly, #PFS on 1st subsequent line for pts receiving daratumumab was 2.2 months for the Isa-Pd arm & 5.7 months for the Pd arm.
— @onc_ce (@onc_ce) February 1, 2023
13) Next in this 🧵, let’s discuss #scientific research that surrounds #BCMA directed therapy in pts w/ #RRMM. Is this the best target for this population? pic.twitter.com/M6tKoVTK80
— @onc_ce (@onc_ce) February 1, 2023
15a) In the Phase 1 #MagnetisMM_1 study , #elranatamab was administered subcutaneously #SC at doses from 80 to 1000µg/kg @either qwk or q2wks. pic.twitter.com/t88JPBHVU6
— @onc_ce (@onc_ce) February 1, 2023
16) In Cohort A of the Phase 2 #MagnetisMM_3 study, as presented by @NizarBahlisMD at #ASH22, both safety and efficacy of #elranatamab appeared promising among pts with #RRMM and no prior #BCMA-directed treatment. pic.twitter.com/fBe5pmm7i4
— @onc_ce (@onc_ce) February 1, 2023
18a) It's CD38! But you knew that! 😉
— @onc_ce (@onc_ce) February 1, 2023
So, 🔑lessons from this #tweetorial:
1⃣ #isatuximab (Isa) appears to be safe & effective when given in combination with #pomalidomide and dexamethasone (Pd) in patients with #RRMM.
19) I am @Bethfaiman and that wraps up my contribution to the #RRMM highlights from #ASH2022! Go to https://t.co/Dd6nBV9yLo to claim your 🆓CE/#CME 🇺🇸🇨🇦🇪🇺🇬🇧. And see the next installment on data from ASH22 from @jmikhaelmd!
— @onc_ce (@onc_ce) February 1, 2023